Depression ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per participant ‐ not measured · participants with cholestatic pruritus (CP)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · children with acute postoperative pain
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · children with acute postoperative pain
2 findings from 1 review
Adverse events (reported in the first 7 days after the procedure) · children with acute postoperative pain
Ibuprofen showed no clear difference in adverse events (reported in the first 7 days after the procedure) compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Survival Log‐rank analysis Study enrolment to last date of · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Adverse events NRS (scale from 0 to 10; lower score = less toxicity) · adults aged 18 years and older receiving palliative care
1 finding from 1 review
Fatigue relief ( · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Serious adverse events · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
QoL · adults with advanced cancer and cancer‐related fatigue
1 finding from 1 review
Intervention not reported
Total studies: 42 Total participants: 14,626 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
The intervention led to lower total studies: 42 Total participants: 14,626; GRADE not reported.
1 finding from 1 review
no estimate extracted
42 participants
GRADE not reported
Intervention not reported
Desvenlafaxine high dose RCTs: 2 Participants: 870 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
50 participants
GRADE not reported
Intervention not reported
Duloxetine high dose RCTs: 14 Participants: 3683 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
14 participants
Low
Intervention not reported
Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
18 participants
Moderate
Intervention not reported
Milnacipran high dose RCTs: 2 Participants: 1670 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
4 participants
Moderate